CAR-T therapy is becoming a more frequent treatment for Medicare patients with diffuse large B-cell lymphoma, but changes in CAR-T treatments that push it as an earlier line of therapy may change where patients receive the therapy — and ultimately, its cost.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
